Tonix Pharmaceuticals Holding Corp. (TNXP)
|Net Income (ttm)||-79.76M|
|Day's Range||0.481 - 0.510|
|52-Week Range||0.501 - 2.120|
|Price Target||3.75 (+642.6%)|
|Earnings Date||Nov 8, 2021|
Tonix Pharmaceuticals Holding Corp. discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replic... [Read more...]
Financial PerformanceFinancial Statements
According to one analyst, the rating for TNXP stock is "Strong Buy" and the 12-month stock price forecast is 3.75.
The company's path to regulatory approval for a key pipeline drug just got a bit shorter.
The FDA has signed off Tonix Pharmaceuticals Holding Corp's (NASDAQ: TNXP) Investigational New Drug (IND) Application to initiate Phase 2 study of TNX-1900 for migraine. TNX-1900 is intranasal potentia...
TNXP stock is soaring 20% on Tuesday after Tonix Pharmaceuticals' treatment for migraines received a key FDA clearance. The post TNXP Stock Alert: The Migraine News Sending Tonix Pharmaceuticals Soaring...
Tonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Preve...
Approximately Four Million in U.S. Suffer from Chronic Migraine
Tonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight
Early Studies in vitro Show that TNX-3500 is a Potent Antiviral Against Multiple Variants of SARS-CoV-2, the Cause of COVID-19, and Potentiates Remdesivir Early Studies in vitro Show that TNX-3500 is a ...
The company secures a potentially crucial piece of intellectual property.
Tonix Pharmaceuticals Presents Phase 1 Formulation Development Data for TNX-601 CR in a Poster Presentation at CNS Su...
Phase 2 Trial of TNX-601 CR for the Treatment of Major Depressive Disorder Expected to Start First Half 2022 Phase 2 Trial of TNX-601 CR for the Treatment of Major Depressive Disorder Expected to Start ...
Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromy...
CHATHAM, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an oral presentati...
Expansion of Internal Research and Development Capabilities Underway to Accelerate Infectious Disease Programs and Prepare for Future Pandemic Responses
Biotech penny stocks to watch with upcoming events this week. The post 5 Penny Stocks To Watch For November With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Inform...
Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Infectious Disease R&D Center in Maryland
Internal R&D Capabilities Expected to Support U.S. Pandemic Preparedness with Accelerated Discovery and Development of Vaccines and Antivirals Against COVID-19 and Other Infectious Diseases
CHATHAM, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced that Seth Lederman, M.D....
Tonix Pharmaceuticals Announces Completion of Acquisition of Infectious Disease R&D Center in Frederick, Maryland
R&D Center is Expected to Accelerate Internal Discovery and Development of Vaccines and Antiviral Drugs Against COVID-19, its Variants and Other Infectious Diseases
Tonix Pharmaceuticals Expands Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines a...
Collaboration Will Continue to Work Towards Identifying Biomarkers for Protective Immunity Against SARS-CoV-2
CHATHAM, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederma...
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) announced that it received the official written response from a Type B pre-Investigational New Drug (IND) meeting with the FDA for its COVID-19 vaccine ...
The notion that groups of individual investors can consistently organize efforts to push stock prices around is starting to crumble. At some point, companies must prove their stock's value.
The stocks have been active ever since the FDA announced full approval of a COVID-19 vaccine.
The positive vaccine news seems to have kick-started meme stocks again.
Are tech penny stocks worth it or not? Check these 4 out for your watchlist The post Best Penny Stocks to Buy Today?
Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) received the official minutes from a Type B pre-Investigational New Drug Application (IND) meeting with the FDA. The meeting was related to TNX-102 SL1 ...
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long ...
Company Plans to Submit an IND to Support a Phase 2 Clinical Trial of TNX-102 SL for the Treatment of Long COVID
Monday's coronavirus vaccine news was a real shot in the arm for the trio.
Central Nervous System Pipeline Progressing with Two Phase 2 Studies (TNX-1300 and TNX-1900) and One Phase 3 Study (TNX-102 SL) Expected to Start This Year
The small drugmaker is moving forward after disappointing clinical results.